The oestrogen receptor

A question about where the hormone went

By the early twentieth century it was already clear that some breast cancers depended on the body's hormonal environment. George Beatson had shown in 1896 that removing the ovaries caused certain advanced tumours to shrink — a result so unexpected that it changed how physicians thought about the disease's biology, even though nobody could explain the mechanism. For decades the connection remained clinical lore: oophorectomy worked in some women and not others, and there was no way to predict which before the operation.

The explanation required someone to ask a simpler, more precise question: where, physically, does oestrogen go inside a cell? Elwood Jensen, a biochemist at the University of Chicago, began pursuing that question in the early 1950s. His motivation was not breast cancer specifically but a fundamental puzzle in endocrinology — how a molecule circulating in blood could produce such specific effects in particular tissues. Jensen's approach was to label oestradiol, the dominant form of oestrogen, with a radioactive tracer and follow it. The experiments, refined through the late 1950s, showed that target tissues — uterus, vagina, certain breast cells — retained the labelled hormone in a way that non-target tissues did not. Something was binding it selectively and holding it.

By 1962, Jensen and his colleagues had gathered enough evidence to propose that a specific intracellular protein was responsible: a receptor that bound oestrogen with high affinity and then, in some fashion, transmitted a signal to the nucleus. The idea was not immediately accepted. The biochemical mainstream was sceptical that a single protein could account for the whole chain from circulating hormone to gene expression, and Jensen spent years marshalling the experimental case. The receptor was eventually isolated, characterised and shown to behave as he had described: oestrogen binds, the receptor-hormone complex enters the nucleus, and gene transcription is altered.

From biology to bedside measurement

The significance for breast cancer became practical once it was possible to measure the receptor's presence in a tumour. If a tumour contained oestrogen receptors — was, in the clinical shorthand, ER-positive — it depended at least partly on oestrogen signalling for growth. If it lacked them, blocking oestrogen would be irrelevant. The receptor was not just a biological fact; it was a predictor, and predictors had immediate clinical use.

The assay that made measurement routine was developed through the late 1960s and 1970s. It used a competitive binding method — the same radioligand logic Jensen had applied to tissue studies — and required a piece of fresh tumour. The technique spread through oncology units in the United States and Europe during the 1970s, and it did something unprecedented for the field: it gave clinicians a way to stratify patients before choosing a hormonal treatment. The National Cancer Institute supported large validation studies during this period, and the NSABP incorporated receptor status into its trial designs, which meant that the emerging evidence base for tamoxifen was being built on receptor-positive populations from early on.

The magnitude of the difference that receptor status made is visible in the Oxford overviews — the periodic meta-analyses conducted by the Early Breast Cancer Trialists' Collaborative Group since the 1980s. Tamoxifen reduced annual recurrence rates substantially in ER-positive disease and had essentially no detectable effect in ER-negative disease. That is not a subtle finding. It means the receptor is doing real biological work, not merely correlating with some other variable, and it means that knowing its status is clinically decisive in a way that few single-protein measurements in oncology can claim.

Later assays moved from biochemical binding methods to immunohistochemistry — antibodies that stain receptor protein directly on a pathology slide, allowing measurement on fixed, paraffin-embedded tissue rather than fresh frozen samples. This shift made receptor testing far more practical and far more widely available. The result reported by the pathologist — a percentage of cells staining positive, and a staining intensity score — feeds directly into treatment decisions. Even a low proportion of positive cells, a threshold debated over the years and still not entirely resolved, is considered clinically significant by most current guidelines.

The receptor as a classification principle

The deeper consequence of Jensen's discovery was that it divided a disease that had been treated as a single entity. Breast cancer diagnosed under a microscope as invasive ductal carcinoma, say, could be ER-positive or ER-negative, and those two tumours behaved differently, responded to different treatments, and had different long-term trajectories. Receptor status became the first molecular variable to be routinely integrated into clinical classification — preceding the routine measurement of HER2 by roughly two decades and preceding the gene expression profiling that would generate molecular subtypes by roughly three.

This matters for how the history of the disease is read. The shift from purely anatomical classification — where a tumour's identity was its location and its microscopic appearance — to receptor-based classification happened not with the sequencing of the genome or the arrival of molecular biology as a prestigious discipline, but with a protein-binding experiment carried out by a biochemist asking where a hormone went. Jensen's methods were not genomic; they were biochemical and painstaking. The conceptual break they produced was nonetheless as large as any that followed.

The receptor itself belongs to a family of nuclear hormone receptors — proteins that act, when activated, as transcription factors, directly regulating which genes a cell reads. Understanding its structure and mechanism occupied molecular biologists for decades after Jensen's initial identification. The gene encoding it, ESR1, sits on chromosome 6, and mutations in that gene have become a focus of research into the mechanisms by which tumours that are initially ER-positive develop resistance to hormonal treatment over time. That late chapter — ESR1 mutations as a resistance mechanism — was not anticipated in the 1960s, but it grows directly from the same foundational observation: this receptor is where the biology lives.

The weight of a single measurement

It is worth pausing on what routine receptor measurement actually changed in practice. Before it, the decision to offer hormonal treatment — initially oophorectomy or adrenalectomy, later tamoxifen — was made empirically, and roughly a third of patients responded. After it, the selection of ER-positive patients for hormonal therapy produced response rates in clinical trials of around 50 to 60 percent, a figure cited in NSABP reporting from the late 1970s onward. The unresponsive two-thirds of the older empirical series included, in large part, the ER-negative patients who should not have received the treatment at all.

Oestrogen receptor status is now measured as a matter of course in every newly diagnosed invasive breast cancer and in most cases of in situ disease. It determines whether hormonal therapy is offered. It shapes the interpretation of prognosis. It was the first step toward the idea that knowing the molecular character of a tumour — not just its size and its appearance under the microscope — is part of what breast cancer diagnosis means. Elwood Jensen did not set out to reshape oncology; he set out to find where a hormone went. The two things turned out to be the same inquiry.